Brainstorm cell therapeutics and catalent announce completion of technology transfer for nurown® manufacturing

New york and somerset, n.j., dec. 7, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, and catalent (nyse: ctlt), a global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that the technology transfer for nurown® manufacturing at catalent's facility has been finalized.
BCLI Ratings Summary
BCLI Quant Ranking